Skip to main content
Category

Uncategorized

crp-header-250

BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process

By Uncategorized

– Multiple SBIR/STTR Submission Deadlines Quickly Approaching –

crp-header-250BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI’s CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.

“The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions,” said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.

“At the end of the day, it’s about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding,” he added.

The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company’s submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.

Interested life science companies in Central Maryland should contact BHI today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.

Rick Soni

By Uncategorized

Rick Soni is the President and Chief Operating Officer of Rexahn Pharmaceuticals, a publically-traded clinical stage biopharmaceutical company. He has held this position since August, 2009. Prior to that, he also served as Chief Business Officer from July 2008 to August 2009. While at Rexahn, Mr. Soni has been instrumental in transforming Rexahn from a discovery stage company to a clinical stage company and has formed a major licensing partnership between Rexahn and Teva Pharmaceuticals.

Prior to joining Rexahn, Mr. Soni held various management positions within Otsuka from June 1997 until July 2008 and was responsible for development and commercialization of otsuka’s successful product portfolio. Prior to Otsuka, Mr. Soni also held several management roles within New Product Planning, Sales and Marketing at Novartis and Schering-Plough (now Merck).

Mr. Soni received his undergraduate degree in Industrial Engineering from University of Wisconsin- Madison and an MBA from Fairleigh Dickinson University.

Medimmune logo

AstraZeneca to add 300 jobs at Gaithersburg’s MedImmune campus – Gazette.Net

By Uncategorized

Medimmune logo

Biopharmaceutical giant AstraZeneca announced today it plans to create a research and development center in Gaithersburg, adding 300 jobs at MedImmune’s current location.

MedImmune’s director of corporate public relations, Tracy Rossin, said no new buildings are planned at this point. Biotech company MedImmune, which is owned by AstraZeneca, currently houses AstraZeneca’s biologics programs, geared toward the creation of vaccines and medications.

Read More
Jim Hughes

Jim Hughes

By Uncategorized

Jim HughesVice President, R&D, University of Maryland, Baltimore

Jim Hughes became Vice President of Research and Development for the University of Maryland, Baltimore (UMB) in December 2001. UMB’s nationally prominent schools of dentistry, law, medicine, nursing, pharmacy, and social work make it one of the top ten public academic healthcare centers in the country. Mr. Hughes’ office is responsible for expanding and administering sponsored research and technology commercialization at UMB. He is also leading UMB’s efforts to develop the UMB Bio Park, an ten-acre, one million square-foot research park that will employ over 2500 people. Prior to joining UMB, Mr. Hughes worked for the Maryland Department of Business and Economic Development (DBED) for six years, most recently as director of Technology and International Business. He led DBED’s efforts to recruit foreign-based businesses and technology-driven businesses to locate facilities in Maryland. Mr. Hughes has an MBA from the Columbia Business School and a BA from Davidson College.

life-sciences-xconomy

East Coast Life Sciences Roundup: GSK, Protein Sciences, IMS Health – Xconomy

By Uncategorized

life-sciences-xconomyOne big East Coast pharmaceutical firm abandoned work on a hepatitis C drug this week, while another shuttered a young company that had cost it $720 million to acquire. But new ideas continue to burst forth, and investors pitched in $20 million for another hopeful startup.

The Connecticut company that figured out how to make a recombinant flu vaccine is now trying to invent a marketing strategy for it. And in New Jersey, one of the biggest sources of marketing data for drug companies snapped up a startup that helps organize all that information.

Read More

Acute Kidney Injury in Older Adults (R21) – May 08, 2016

By Uncategorized

Funding Opportunity Number: PA-13-143
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.866
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: May 07, 2016
Award Ceiling: $200,000
Expected Number of Awards:
Creation Date: Mar 14, 2013
Funding Opportunity Description: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, translational and outcomes research on acute kidney injury (AKI) in older persons. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Applications may focus on the 1) epidemiology, etiology and risk factors for AKI in older adults, 2) pathophysiology of AKI in the aging kidney and its impact on chronic kidney disease (CKD) and other organ disease 3) early detection, diagnosis and monitoring of AKI, and 4) prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes including morbidity, mortality, progression of CKD, functional independence and quality of life. Research supported by this initiative should enhance knowledge of the increasing incidence of AKI in older persons and its consequences and provide evidence-based guidance in the diagnosis, prevention, and treatment of AKI in this expanding segment of the population. Studies in both human subjects and animal models are appropriate under this FOA as warranted by the study questions.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=227088

Read More

Acute Kidney Injury in Older Adults (R03) – May 08, 2016

By Uncategorized

Funding Opportunity Number: PA-13-142
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.866
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: May 07, 2016
Award Ceiling: $100,000
Expected Number of Awards:
Creation Date: Mar 14, 2013
Funding Opportunity Description: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, translational and outcomes research on acute kidney injury (AKI) in older persons. This funding initiative supports small research projects that can be carried out in a short period of time with limited resources including pilot and feasibility studies, secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applications may focus on the 1) epidemiology, etiology and risk factors for AKI in older adults, 2) pathophysiology of AKI in the aging kidney and its impact on chronic kidney disease (CKD) and other organ disease 3) early detection, diagnosis and monitoring of AKI, and 4) prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes including morbidity, mortality, progression of CKD, functional independence and quality of life. Research supported by this initiative should enhance knowledge of the increasing incidence of AKI in older persons and its consequences and provide evidence-based guidance in the diagnosis, prevention, and treatment of AKI in this expanding segment of the population. Studies in both human subjects and animal models are appropriate under this FOA as warranted by the study questions.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=227087

Read More

Acute Kidney Injury in Older Adults (R01) – May 07, 2016

By Uncategorized

Funding Opportunity Number: PA-13-141
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Food and Nutrition
Health
CFDA Number: 93.847
93.866
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: May 07, 2016
Award Ceiling:
Expected Number of Awards:
Creation Date: Mar 14, 2013
Funding Opportunity Description: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, translational and outcomes research on acute kidney injury (AKI) in older persons. Applications may focus on the 1) epidemiology, etiology and risk factors for AKI in older adults, 2) pathophysiology of AKI in the aging kidney and its impact on chronic kidney disease (CKD) and other organ disease 3) early detection, diagnosis and monitoring of AKI, and 4) prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes including morbidity, mortality, progression of CKD, functional independence and quality of life. Research supported by this initiative should enhance knowledge of the increasing incidence of AKI in older persons and its consequences and provide evidence-based guidance in the diagnosis, prevention, and treatment of AKI in this expanding segment of the population. Studies in both human subjects and animal models are appropriate under this FOA as warranted by the study questions.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=227086

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.